Estrogen Receptor β as a Pharmaceutical Target

详细信息    查看全文

• 作者：Margaret Warner¹ ; Bo Huang¹ ; Jan-Ake Gustafsson¹ ; ² ; ^{jgustafs@Central.UH.EDU}
• 刊名：Trends in Pharmacological Sciences
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：38
• 期：1
• 页码：92-99
• 全文大小：2342 K
• 卷排序：38

文摘

A major issue in clinical endocrinology today is how to use hormones to achieve the health benefits that they clearly can provide but avoid the negative side effects, that is, how to develop more precise medicines. This problem of how to use hormones is pervasive in clinical endocrinology. It is true for estrogen, progesterone, androgen, vitamin D, and thyroid hormone, and the problem is amplified in the case of new ligands for the more recently discovered nuclear receptors. Selective targeting of hormone receptor subtypes is one attractive way to harness the beneficial effects of hormones while reducing unwanted side effects. Here, we focus on estrogen receptor (ER)β, which has promise as a selective target in hormone replacement therapy, and in breast and prostate cancers.